Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Pastimes : Home on the range where the buffalo roam -- Ignore unavailable to you. Want to Upgrade?

To: allen menglin chen who wrote (2706)	6/26/2000 7:55:00 AM
From: Boplicity	Respond to of 13572

NO, I hope to hold it long time. You are being funny, right? :) Greg

To: allen menglin chen who wrote (2706)	6/26/2000 9:55:00 AM
From: Boplicity	Read Replies (1) \| Respond to of 13572

The Bull Market Drug & Biotech Investor - bull-market.com THE BULL MARKET BIOTECH INVESTOR for Sunday, June 25, 2000 Volume 7, #6 bull-market.com =================== Sponsor ==================== GET A NEXTCARD VISA, in 30 seconds! Get rates as low as 2.9% Intro or 9.9% Fixed APR and no hidden fees. Apply NOW! nextcard.com ================================================= The Bull Market Biotech Investor is a periodic series of discussions of the changing Biotech and Pharmaceutical world we live in and the companies that are going to profit from these changes. The Bull Market Report web site has links to The Bull Market Biotech Investor (http://www.Bull-Market.com). The site includes The Bull Market Biotech Portfolio (with 12-month price targets for its 21 stocks), and all issues of The Bull Market Biotech Investor, including today's. Descriptions of the companies and links to their web sites accompany the Portfolio. We try to cover some of the most relevant news relating to investment potential in the healthcare industry, and particularly to the companies in our Portfolio. Just because we haven't mentioned an event or a company doesn't mean we don't think it's important! ================================================= ================================================= DISCUSSION In last weekend's edition of The Bull Market Biotech Investor, we noted the peculiar strength demonstrated by Biotech stocks on three consecutive Fridays in June. Well, as soon as we mentioned it, the streak came to an end. When it seems that all we need is a fistful of darts and a few press releases, the sector begins to experience a pullback. On days that the Nasdaq exhibits great strength, investors like to see stocks of the big high technology companies leading the charge: stocks such as Intel, Cisco, Microsoft and Dell. On a similar note, when Biotech stocks begin moving higher, we like to see the larger companies (the familiar names) leading the sector. This pattern did occur at the beginning of last week, but by the middle of the week the sector began to lose its strength as investors took profits in stocks of the larger Biotechs. In an effort to provide more technical information to our readers, we are providing in our weekend edition a list of the best performing Biotechnology stocks. Our aim is to provide a recap of some of the week's highlights in the Biotechnology sector as well as some technical information regarding Biotech stocks. The following is a list of last week's best performing Biotech and Pharmaceutical stocks according to percentage change in price. Company Symbol Close Change %Chg. Lexicon Genet LEXG $24 10 76 OSI Pharma OSIP 24 8 49 Cytoclonal Ph CYPH 11 4 45 Sequenom SQNM 48 13 37 Alexion Ph ALXN 58 14 31 Arqule ARQL 14 3 31 Pharmacopeia PCOP 34 7 25 Immunogen IMGN 12 2 22 Magainin Ph MAGN 5 1 21 Cytogen CYTO 10 2 21 Abgenix ABGX 138 24 21 Agilent Tech A 75 13 20 Geron GERN 33 6 20 Genzyme Trans GZTC 28 5 20 Celera CRA 127 21 20 Orchid BioSci ORCH 26 4 19 Immune Resp IMNR 9 1 18 Progenics PGNX 15 2 18 Tularik TLRK 30 4 16 Immunomedics IMMU 22 3 15 Valentis VLTS 10 1 14 Genome Thera GENE 30 4 14 Genelabs GNLB 5 1 14 Genentech DNA 150 18 13 Repligen RGEN 6 1 13 Texas Biotec TXB 16 2 13 ALZA AZA 56 6 13 Enzo Biochem ENZ 68 8 13 Immunex IMNX 50 6 13 Curagen CRGN 40 5 13 Targeted Gen TGEN 12 1 12 Cubist Pharm CBST 44 5 12 LEXICON GENETICS The big winner of the week was Lexicon Genetics (LEXG) advancing 76%. The company put out a press release on Tuesday morning stating that they had genetically altered over one-third of the genes in the mouse genome. The value of having thousands of genetically altered clones (each mouse genome containing a mutation is referred to as a clone) is that it can speed up the process of determining the function of specific genes. Since there is a high degree of homology between the mouse and human genomes, the information that is garnered from studying the function of genes in murine models may be applicable to human models. Also on Tuesday, CIBC World Markets reiterated a "Strong Buy" recommendation on Lexicon Genetics with a 12-month price target of $30 (not a huge upside target). We discussed Lexicon Genetics in the June 22nd edition of The Bull Market Biotech Investor and that can be read at our website. OSI PHARMACEUTICALS OSI Pharmaceuticals (OSIP) advanced 49% on the week with the entire gain being acquired on Monday. Due to the merger of Pfizer and Warner-Lambert, the Federal Trade Commission is requiring Pfizer to grant a potential cancer therapeutic to OSI Pharmaceuticals. The anti-cancer agent is a growth factor inhibitor; a member of a class of compounds that show much promise. On Tuesday, both Robertson Stephens and Prudential put out "Strong Buy" ratings on the company. However, Robertson Stephens lowered FY00 and FY01 earnings estimates for OSIP because of the expected increased research costs associated with further development of the growth inhibitor. We would guess that if the market is weak this week, you may get to buy OSI at a lower level. CYTOCLONAL PHARMACEUTICALS The stock of Cytoclonal Pharmaceuticals (CYTO) was silent all week until Friday when the company issued a press release stating the development of an inhibitor of the BCL cancer gene. The stock price added 3.5 points to $11. Cytoclonal Pharmaceuticals has a proprietary technology termed OASIS (optimum anti-sense reagents) that is used to generate Anti-sense molecules. Anti-sense molecules are synthetic pieces of genetic material that are complementary to normal gene sequences. The Anti-sense molecule can thus bind to the normal gene sequence and render it ineffective for making protein. A possibility for the company is to use its OASIS technology to create a library of Anti-sense molecules to all human genes. This would be a large task; however, it should be possible to generate effective Anti-sense molecules to many genes related to human disease. HUMAN GENOME SCIENCES Although Human Genome Sciences (HGSI, +9%) was not one of the top percentage gainers in our list above, the company issued a significant press release concerning the initiation of human clinical trials for its BlyS protein. To give you an idea of the pace at which science travels from the laboratory bench to an approved drug, it was last July that Human Genome Sciences published a paper in SCIENCE magazine describing the discovery BlyS: a human protein that induces the growth of B cells and the secretion of antibodies from those cells. We can assume that the company had spent at least the previous year performing the science that led the publication. So, after at least two years of work, the company is ready to begin a clinical trial -- actually a fast pace for science. It could take another four years before BlyS, if efficacious, finishes a phase III clinical test. Human clinical trials will commence with individuals with Common Variable Immunodeficiency. This disease is characterized by the inability of patients to produce enough antibodies to ward off infections. The objective is to discern whether treatment of these immunodeficient individuals with BlyS will restore or enhance their production of antibodies. In addition, there is the hope that BlyS will be applicable to other human diseases or immunodeficiencies characterized by B cell disorders such as autoimmunity (when individuals make antibodies against their own "self" proteins) and cancer. ================================================= ================================================= Don't forget that on Monday there is expected an announcement that the Human Genome Project has finished a rough draft of the human genetic sequence. Celera Genomics has been in a race with the government-sponsored Genome Project and it is expected but unknown whether Celera will be involved with the announcement. Either way, if an announcement is made, it should make for an interesting day for stocks of companies involved with genomics. Robert Mendoza, Ph.D. Contributing Editor The Bull Market Biotech Investor Mendoza@Bull-Market.com Biography. Robert Mendoza has monitored and made investments in the Biotech sector since 1985. Dr. Mendoza is currently a research scientist at the University of California San Diego and is developing models for the gene therapy of cancer. Robert earned a doctoral degree in Molecular Biology at the University of California Berkeley and also holds a Master's degree in Chemistry from the California State University at Fullerton. At the current time, Dr. Mendoza does not hold a position in the companies discussed in this article.. ================================================= ================================================= 2. PORTFOLIO TRACKER The Bull Market Biotech Investor Portfolio: The columns indicate the closing price for stocks on June 16th and June 23rd, the change in price and the percentage change. The %YTD represents the percentage year-to-date change for each security. Name Symbol 6/16 6/23 Chg. %Chg. %YTD Affymetrix AFFX 175 176 1 1 4 ALZA AZA 50 56 6 13 15 Amgen AMGN 68 67 1 -2 11 Biotech HLDR BBH 164 172 8 5 20 Biomira BIOM 10 10 0 0 140 B-M Squibb BMY 53 54 1 2 -16 Celera Genomics CRA 106 127 21 20 -15 Chiron CHIR 43 44 1 2 19 EntreMed ENMD 26 28 2 10 -15 Gene Logic GLGC 36 39 3 8 11 Genentech DNA 132 150 18 13 12 Gilead Sciences GILD 66 69 3 6 28 Human Genome Sci HGSI 134 145 12 9 90 Imclone Systems IMCL 82 81 -1 -1 104 Maxygen MAXY 56 62 6 11 -23 MedImmune MEDI 70 70 0 0 27 Millennium MLNM 120 120 0 0 96 Merck MRK 71 73 2 2 9 Pfizer PFE 48 46 -2 -4 42 Phrmceutcl HLDR PPH 99 98 -1 -1 8 ViroPharma VPHM 15 14 -1 -4 -60 The portfolio has achieved a year-to-date gain of 15.4%. *These securities were added to the portfolio after the beginning of the year. The %YTD reflects the percent return since being added to the portfolio. Good Biotech investing! Todd Shaver Editor in Chief The Bull Market Report Washington, DC USA ================================================= ================================================= Have you tried THE BULL MARKET REPORT DAILY? Click here for a two-week free trial: bull-market.com -or- send an email request to Susan@Bull-Market.com with "FREE TRIAL" in the subject line. ================================================= SUBSCRIPTION INFORMATION If you are not a subscriber, click here to subscribe to The Bull Market Biotech Investor: bull-market.com; If you like this newsletter, why not subscribe to the entire Investor Series? They come out weekly and are free! The Bull Market Biotech Investor The Bull Market Wireless Investor The Bull Market Financial Services Investor The Internet Investor The Bull Market Technical Investor Visit our subscription page at: bull-market.com -or- send an email request to Susan@Bull-Market.com with "Subscribe-Series" in the subject line. To UNSUBSCRIBE from this newsletter, click here: bull-market.com -or- send an email request to Susan@Bull-Market.com with "Unsubscribe-Biotech" in the subject line. ================================================= ================================================= Disclaimer: Todd Shaver and other contributors to this newsletter may hold positions in securities mentioned in The Bull Market Biotech Investor for purposes of investment or trading. All information contained in the newsletter is obtained from public sources. The sources used are believed to be reliable but the accuracy of this information is not guaranteed. The Bull Market Report, LLC is not a registered Investment Adviser or a Broker/Dealer. Readers are advised that the report is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy. The opinions and analyses included herein are based from sources believed to be reliable and written in good faith, but no representation or warranty, expressed or implied is made as to their accuracy, completeness or correctness. Readers are urged to consult with their own independent financial advisors with respect to any investment. All information contained in this report should be independently verified with the companies mentioned. In addition, The Bull Market Report is taking no compensation of any kind from any companies that we mention in this report. (C) Copyright 2000 The Bull Market Biotech Investor and The Bull Market Report, LLC. _________________________________________________________ Start Your Own FREE Email List at listbot.com

To: allen menglin chen who wrote (2706)	6/26/2000 6:11:00 PM
From: Boplicity	Read Replies (2) \| Respond to of 13572

Allen, This is right up my ally. I'm going to buy a basket of these then widdle them away or keep them as I watch them perform. I just started looking close at this, so I have no idea which of the below are worth investing in if at all. I'll post here on what I find after I do my DD tonight. If you have anything to add please let me know. And thanks, Greg <<Genomics tool makers move into spotlight By Deena Beasley LOS ANGELES, June 26 (Reuters) - With a working map of the human genome in hand, scientists are moving on to the daunting job of figuring out the function of each gene, a task some expect to shift the biotech spotlight onto so-called "genomics tool" companies. "This is sort of like the Gold Rush days. During the gold rush what you really wanted to be into were the folks who sold the picks and shovels. A lot of people thought they'd strike gold, but the ones that were really making money in the short term were the ones that sold picks and shovels," said Erick Lucera, an analyst at Independence Investment Advisors. This time, the mining equipment is more likely to be high- volume computer systems, scanners and other instruments that are able to organize and analyze huge amounts of genetic data, extracting only the most valuable nuggets. Celera Genomics <CRA.N>, a Rockville, Md.-based company founded with the specific purpose of being the first to map the human genome, said on Monday it had finished the sequence and assembled the genetic code. The Human Genome Project, a publicly funded international effort that has been working toward the same goal, said it had finished a rough draft of the genome sequence and completed 85 percent of the assembly. The achievement is only the first step of a decades-long process that scientists say will transform medicine by allowing doctors to tailor drugs for each individual and to predict who is at risk of certain diseases. "The puzzle pieces are coming together. This allows researchers to have a frame of reference for their discoveries," said Michael Becker, an analyst at Wayne Hummer Investments. No matter who the winners are in the in the race to discover new drugs, some analysts say investors may be well served by companies that provide tools for sifting through the huge volumes of genetic data. For the next couple of years, investors should focus on tool makers, like Waters Corp. <WAT.N>, or PE Biosystems <PEB.N>, that are likely to snag a portion of the research money being funneled to genomics screening, Lucera said. "The demand for sequencing is only going to increase -- we estimate by a 20 percent compound annual basis -- for the foreseeable future," said Paul Kelly, an analyst at ING Barings. He too named PE Biosystems, the systems unit of PE Corp., which is also the parent of Celera Genomics, along with Affymetrix Inc. <AFFX.O>, a Santa Clara, Calif.-based firm that makes systems to acquire, analyze and manage genetic information, as companies likely to benefit from the milestone sequencing announcement. "While this important milestone should not be understated, it is important to now support the massive effort required to examine the genomes of hundreds to thousands of individuals to uncover human variation and its consequences for human disease. The effort to understand these variations will dwarf the initial task of sequencing the genome," Stephen Fodor, chairman of Affymetrix, said in a statement. Affymetrix' GeneChip technology allows researchers to pinpoint the function of newly discovered genes. Another company likely to do well is Sangamo Biosciences Inc. <SGMO.O>, which makes technology products used to identify and evaluate genes and the proteins that regulate them, Kelly said. "All drugs on the market today interact with proteins," said Becker. "Insulin is a protein key to diabetes. There are also proteins that regulate genes related to Alzheimer's and cancer." And once those proteins are discovered, researchers will need to find the chemical entities to interfere with them. Becker expects genomics companies like Celera, tool companies and biotechnology companies to eventually come together to form drug discovery conglomerates. "There will be a lot of mergers and acquisitions of complementary technologies," the analyst said. "It's similar to the software industry," Becker added. Microsoft moved into spreadsheets, word processing and databases, eventually offering everything to its customers."